Pharmacological Basis for the Therapy of Osteoarthritis

  • J. Steinmeyer
Conference paper


For a targeted pharmacologically oriented basic therapy for osteoarthritis, it is important that the drugs should act against the underlying process of cartilage destruction. A deep insight and exact knowledge of the pathogenetic reactions that occur during the course of degenerative joint disease are necessary for the development of such agents. Fortunately, from the field of experimental osteoarthritis research, a large number of new and interesting findings have come to light over the last 5–10 years concerning the pathogenesis of osteoarthritic joint dysfunction. In order to illustrate the present possible starting points for a pharmacological intervention, some aspects of the pathogenesis of osteoarthritis is first briefly described as it is currently understood.


Articular Cartilage Hyaluronic Acid Synovial Fluid Sodium Hyaluronate Pharmacological Basis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akatsuka M, Yamamoto Y, Tobetto K, Yasui T, Ando T (1993) In vitro effects of hyaluronan on prostaglandin E2 induction by interleukin-1 in rabbit articular chondrocytes. Agents Action 38: 122–125CrossRefGoogle Scholar
  2. Annefeld M, Fassbender HG (1983) Ultrastructural study of the activity of antiarthritic substances. Z Rheumatol 42: 199–202PubMedGoogle Scholar
  3. Armstrong S, Read R, Ghosh P (1994) The effects of intraarticular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol 21: 680–688PubMedGoogle Scholar
  4. Bach G (1996) Arthrose-Medikamente mit verzögertem Wirkungseintritt. In: Gräfenstein K (ed) Therapie rheumatischer Erkrankungen. Ecomed, Landsberg/Lech, pp 66–70Google Scholar
  5. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC (1987) Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med 83: 55–59PubMedCrossRefGoogle Scholar
  6. Bassleer C, Reginster JY, Franchimont P (1993) Effects of glucosamine on differentiated human chondrocytes cultivated in clusters. Rev Esp Reumatol 20 [Suppl 11]:Mo95Google Scholar
  7. Dougados M (1996) On behalf of the Group for the Respect of Ethics and Excellence in Science (GREES), osteoarthritis section, Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 55: 552–557CrossRefGoogle Scholar
  8. Engfeldt B, Hjertquist S-O (1967) The effect of various fixatives on the preservation of acid glycosaminoglycans in tissues. Pathol Microbiol Scand 171: 219–232Google Scholar
  9. Ghosh P, Holbert C, Read R, Armstrong S (1995) Hyaluronic acid (hyaluronan) in experimental osteoarthritis. J Rheumatol 43 [Suppl]: 155–157Google Scholar
  10. Ghosh P (1994) The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheum 12: 75–82Google Scholar
  11. Gotoh S, Miyazaki K, Onaya J, Sakamoto T, Tokuyasu K, Namiki O (1988) Experimental knee pain model in rats and analgesic effect of hyaluronate. Nippon Yakurigaku Zasshi 92: 17–27PubMedCrossRefGoogle Scholar
  12. Gualano M, Berti F, Stramentinoli G (1985) Anti-inflammatory activity of S-adenosylL-methionine in animal models: possible interference with the eicosanoid system. Int J Tissue React 7: 41–46PubMedGoogle Scholar
  13. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D (1987) Effects of Sadenosylmethionine on human articular chondrocte differentiation. An in vitro study. Am J Med 83: 48–54PubMedCrossRefGoogle Scholar
  14. Homandberg GA, Hui F, Wen C, Kuettner KE, Williams JM (1997) Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: I. In vitro. Osteoarthritis Cart 5: 309–319CrossRefGoogle Scholar
  15. Hübner F, Steinmeyer J, Kalbhen DA (1997) Pharmacological influence on the collagenolytic activities of articular cartilage. Naunyn-Schmiedebergs Arch Pharmacol 355 [Suppl 4]: R87Google Scholar
  16. Ialante A, Di Rosa M (1994) Hyaluronic acid modulates acute and chronic inflammation. Agents Actions 43: 44–47CrossRefGoogle Scholar
  17. Ionac M, Parnham MJ, Plauchithiu M, Brune K (1996) Oxaceprol, an atypical inhibitor on inflammation and joint damage. Pharmacol Res 33: 367–373PubMedCrossRefGoogle Scholar
  18. Jiménez SA, Dodge GR (1997) The effects of glucosamine sulfate (G504) on human chondrocyte gene expression. Osteoarthritis Cart 5 [Suppl A]: 72Google Scholar
  19. Kalbhen DA, Jansen G (1990) Pharmacologic studies on the antidegenerative effect of ademetionine in experimental arthritis in animals. Arzneim-Forsch/Drug Res 40: 1017–1021Google Scholar
  20. Kalbhen DA, Kalkert B (1987) Autoradiography studies of the effect of oxaceprol on the metabolism of joint cartilage in vitro and in vivo. Z Rheumatol 46: 136–142PubMedGoogle Scholar
  21. Kalbhen DA (1987) Pharmakologische Untersuchungen mit chondroprotektiven Substanzen. In: Miehle W (ed) Chondroprotektion: Fakten and Aspekte. pmi Verlag, Frankfurt, pp 18–21Google Scholar
  22. Kikuchi T, Yamada H, Shimmei M (1996) Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cart 4: 99–110CrossRefGoogle Scholar
  23. Laurent UB, Fraser JR, Engstrom-Laurent A, Reed RK, Dahl LB, Laurent TC (1992) Catabolism of hyaluronan in the knee joint of the rabbit. Matrix 12: 130–136PubMedCrossRefGoogle Scholar
  24. Lequesne M (1993) ILAR guidelines for testing slow acting drugs in osteoarthritis (SADOAs). Rev Esp Rumatol 20 [Suppl 11: 220–221Google Scholar
  25. Lequesne MG, Mery C, Samson M, Gerard P (1987) Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 65 [Supp1]: 85–89CrossRefGoogle Scholar
  26. Mankin HJ, Brandt KD (1997) Pathogenesis of osteoarthritis. In: Kelley WN, Ruddy S, Harris ED, Sledge CB (eds) Textbook of rheumatology. WB Saunders, Philadelphia London, pp 1369–1382Google Scholar
  27. Miyazaki K, Goto S, Okawara H (1984) Sodium hyaluronate (SPH): studies on analgesic and anti-inflammatory effects of sodium hyaluronate. Pharmacometrics 28: 1123–1135Google Scholar
  28. Morris EA, Wilcon S, Treadwell BV (1992) Inhibition of interleukin 1 mediated proteoglycan degradation in bovine articular cartilage explants by addition of sodium hyaluronate. Am J Vet Res 53: 1977–1982PubMedGoogle Scholar
  29. Nagase H, Okada Y (1997) Proteinases and matrix degradation. In: Kelley WN, Ruddy S, Harris ED, Sledge CB (eds) Textbook of rheumatology. WB Saunders, Philadelphia London, pp 323–342Google Scholar
  30. Pelletier J-M, Martel-Pelletier J (1993) The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol 20: 19–24Google Scholar
  31. Pelletier JP, Howell DS (1993) Etiopathogenesis of osteoarthritis. In: McCarthy DJ, Koopman WJ (eds) Arthritis and allied conditions. Lea and Febiger, Philadelphia London, pp 1723–1734Google Scholar
  32. Raiss R (1985) Effect of D-glucosamine sulfate on experimentally injured articular cartilage. Comparative morphometry of the ultrastructure of chondrocytes. Fortschr Med 103: 658–662PubMedGoogle Scholar
  33. Riera H, Aprile F, Mitrovic D (1990) Effect of oxaceprol on the proteoglycan and protein synthesis and degradation by cultured calf articular cartilage explants. Rev Rhum 57: 579–583PubMedGoogle Scholar
  34. Sandy JD, Flannery CR, Neame PJ, Lohmander LS (1992) The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 89: 1512–1516PubMedCrossRefGoogle Scholar
  35. Setnikar I, Cereda R, Pacini MA, Revel L (1991) Antireactive properties of glucosamine sulfate. Arzneim-Forsch/Drug Res 41: 157–161Google Scholar
  36. Setnikar I, Pacini MA, Revel L (1991) Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneim-Forsch/Drug Res 41: 542–545Google Scholar
  37. Shimazu A, Jikko A, Iwamoto M, Koike T, Yan W, Okada Y, Shinmei M, Nakamura S, Kato Y (1993) Effects of hyaluronic acid on the release of proteoglycan from the cell matrix in rabbit chondrocyte cultures in the presence and absence of cytokines. Arthritis Rheum 36: 247–253PubMedCrossRefGoogle Scholar
  38. Shimizu C, Yoshioka M, Coutts RD, Harwood FL, Kubo T, Hirasawa Y, Amiel D (1998) Long-term effects of hyaluronan on experimental osteoarthritis in the rabbit knee. Osteoarthritis Cart 6: 1–9CrossRefGoogle Scholar
  39. Steinmeyer J, Daufeldt S (1997) Pharmacological influence of antirheumatic drugs on the proteoglycans from interleukin-1 treated articular cartilage. Biochem Pharmacol 53: 1627–1635PubMedCrossRefGoogle Scholar
  40. Steinmeyer J, Kim C, Sadowski T, Kalbhen DA (1996) Pharmacological influence on the activity of plasmin and plasminogen activators in vitro. Naunyn-Schmiedebergs Arch Pharmacol 353 [Suppl 4]: R7Google Scholar
  41. Stramentinoli G (1987) Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 83: 35–42PubMedCrossRefGoogle Scholar
  42. Tanaka S, Kumano F, Takayama M, Fukuda K (1997) Hyaluronic acid increases proteoglycan synthesis in articular cartilage degraded by interleukin-1. Osteoarthritis Cart 5 [Suppl A]: 66Google Scholar
  43. Vivien D, Galéra P, Loyau G, Pujol J-P (1993) N-acetyl-4-hydroxyproline (Oxaceprol®) and collagen synthesis in cultured synovial cells and articular cartilage. Osteoarthritis Cart 1: 40Google Scholar
  44. Weischer CH (1987) Antinozizeptive und antiinflammatorische Wirkung von S-Adenosylmethionin (SAMe) nach ein-und mehrmaliger intraperitonealer Applikation. In: Bach GL, Miehlke K (eds) Arthrose Workshop über Gumbaral® (Ademetionin). pmi-Verlag, Frankfurt, pp 81–86Google Scholar
  45. Yasui T, Akatsuka M, Tobetto K, Umemoto J, Ando T, Yamashita K, Hayakawa T (1992) Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 13: 343–348Google Scholar
  46. Yoshioka M, Shimizu C, Harwood FL, Coutts RD, Amiel D (1997) The effect of hyal- uronan during the development of osteoarthritis. Osteoarthritis Cart 5: 257–260CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2000

Authors and Affiliations

  • J. Steinmeyer

There are no affiliations available

Personalised recommendations